Cleveland HeartLab
Cleveland HeartLab (acquired by Quest Diagnostics) is a reference laboratory based on novel biomarker technologies developed at Cleveland Clinic. The company is involved in the discovery and validation of molecular biomarkers and their development into products that aid in the diagnosis and treatment of a variety of diseases. The initial focus is on Myeloperoxidase (MPO), a diagnostic marker of cardiovascular risk, and the company has received 510(k) clearance to market its first biomarker, CardioMPO.